1. Home
  2. DOMH vs ENSC Comparison

DOMH vs ENSC Comparison

Compare DOMH & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DOMH
  • ENSC
  • Stock Information
  • Founded
  • DOMH 1967
  • ENSC 2003
  • Country
  • DOMH United States
  • ENSC United States
  • Employees
  • DOMH 28
  • ENSC N/A
  • Industry
  • DOMH Biotechnology: Pharmaceutical Preparations
  • ENSC Biotechnology: Pharmaceutical Preparations
  • Sector
  • DOMH Health Care
  • ENSC Health Care
  • Exchange
  • DOMH Nasdaq
  • ENSC Nasdaq
  • Market Cap
  • DOMH 74.9M
  • ENSC 7.9M
  • IPO Year
  • DOMH N/A
  • ENSC N/A
  • Fundamental
  • Price
  • DOMH $11.94
  • ENSC $5.80
  • Analyst Decision
  • DOMH
  • ENSC
  • Analyst Count
  • DOMH 0
  • ENSC 0
  • Target Price
  • DOMH N/A
  • ENSC N/A
  • AVG Volume (30 Days)
  • DOMH 4.1M
  • ENSC 53.4K
  • Earning Date
  • DOMH 03-31-2025
  • ENSC 03-14-2025
  • Dividend Yield
  • DOMH N/A
  • ENSC N/A
  • EPS Growth
  • DOMH N/A
  • ENSC N/A
  • EPS
  • DOMH N/A
  • ENSC N/A
  • Revenue
  • DOMH $12,589,000.00
  • ENSC $4,421,404.00
  • Revenue This Year
  • DOMH N/A
  • ENSC $89.78
  • Revenue Next Year
  • DOMH N/A
  • ENSC N/A
  • P/E Ratio
  • DOMH N/A
  • ENSC N/A
  • Revenue Growth
  • DOMH 1117.50
  • ENSC 40.41
  • 52 Week Low
  • DOMH $0.83
  • ENSC $2.12
  • 52 Week High
  • DOMH $13.58
  • ENSC $14.85
  • Technical
  • Relative Strength Index (RSI)
  • DOMH 82.78
  • ENSC 38.42
  • Support Level
  • DOMH $6.31
  • ENSC $5.34
  • Resistance Level
  • DOMH $13.58
  • ENSC $6.46
  • Average True Range (ATR)
  • DOMH 1.72
  • ENSC 0.45
  • MACD
  • DOMH 1.00
  • ENSC -0.07
  • Stochastic Oscillator
  • DOMH 86.16
  • ENSC 20.08

About DOMH Dominari Holdings Inc.

Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company's oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: